Workflow
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
HalozymeHalozyme(US:HALO) Prnewswireยท2025-08-05 20:01

Core Insights - Halozyme Therapeutics reported a significant financial performance for the second quarter of 2025, with total revenue increasing by 41% year-over-year to $326 million, driven by a 65% increase in royalty revenue to $206 million [1][8] - The company raised its financial guidance for 2025, expecting total revenue between $1,275 million and $1,355 million, representing a year-over-year growth of 26% to 33% [11][17] Financial Performance - Net income rose by 77% year-over-year to $165 million, while adjusted EBITDA increased by 65% to $226 million [1][8] - GAAP diluted EPS increased by 85% year-over-year to $1.33, and non-GAAP diluted EPS rose by 69% to $1.54 [1][8] Share Repurchase and Capital Allocation - The company announced the initiation of a third $250 million share repurchase tranche under a $750 million authorized plan, completing a total of $303 million in share repurchases during the second quarter [2][4][7] - Strong cash generation supports a balanced capital allocation strategy, including investments in growth through mergers and acquisitions and returning capital to shareholders [4] Regulatory Approvals and Product Development - The company achieved notable regulatory milestones, including approvals for RYBREVANT SC in Europe and VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy in Europe [3][10] - The ENHANZE drug delivery technology continues to gain traction, with increasing global demand and new indications being approved for existing therapies [3][4] Future Outlook - The updated financial guidance for 2025 includes expectations for royalty revenue between $825 million and $860 million, adjusted EBITDA between $865 million and $915 million, and non-GAAP diluted EPS between $6.00 and $6.40 [11][17] - The company anticipates continued growth driven by its blockbuster therapies and expanding regulatory approvals [3][11]